Leila is Senior Clinical Lecturer in Immunotherapy and Honorary Medical Oncology Consultant. She has worked previously at AstraZeneca and at Addenbrooke’s Hospital and has a rich experience of translating immunotherapies from bench to bedside.
Since October 2020 Leila has been the immunotherapy theme lead for the Birmingham Experimental Cancer Medical Centre (ECMC).
Her work is focused on early phase trials in the field of immunotherapy and with her research interest in melanoma and uveal melanoma. Leila acts as a medical advisor for Cancer Research UK (CRUK).
Leila’s work has focused on trials in the field of immunotherapy and has observed the ways that therapeutic advance in cancer treatment have revolutionised outcomes. She is focused on research on biomarkers in uveal melanoma treatment and in exploring the pre-cancer immune response.
Leila acts as a medical advisor for CRUK, working on the clinical development of specific molecules. Leila’s research work is a mixture of commercial and academic trials, including investigator-led arms/trials. She is part of the scientific advisory board for the Tessa Jowell Brain Matrix study.